Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-25
    E.g., 2018-06-25

Archive Search

257323 items
11:36 AM, Jun 22, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Qiming leads series A for Alpha Biopharma

Alpha Biopharma Inc. (Shanghai, China) raised $37 million in the first tranche of a planned $65 million series A round led by Qiming Venture Partners. The TF Fund and LYZZ Healthcare Venture Fund also participated. Alpha...
11:36 AM, Jun 22, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Qiming leads series B for cancer play WindMIL

WindMIL Therapeutics Inc. (Baltimore, Md.) raised $32.5 million on June 18 in an untranched series B round led by Qiming Venture Partners. Fellow new investors Medivate Partners, Camden Partners Nexus and the Kinneret Group participated...
11:35 AM, Jun 22, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Stealth to start Phase IIb of AMD candidate with $100M financing

Stealth BioTherapeutics Inc. (Newton, Mass.) raised $100 million June 18 through two convertible note rounds led by Nan Fung Technology's Pivotal Beta and Morningside Ventures, respectively. Also participating were funds associated with Atlantis Investment Management,...
11:35 AM, Jun 22, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Emulate raises $36M series C to improve Organ-Chips offering

Emulate Inc. (Boston, Mass.) raised on June 19 $36 million in a series C round led by Founders Fund. Fellow new investors ALS Investment Fund, SciFi VC and Glass Wall Syndicate also participated, as did...
11:27 AM, Jun 22, 2018  |  BC Week In Review | Clinical News  |  Regulatory

FDA lifts clinical hold on Solid's DMD gene therapy

Solid Biosciences Inc. (NASDAQ:SLDB) said FDA lifted a clinical hold on the Phase I/II IGNITE DMD trial of microdystrophin gene transfer therapy SGT-001 to treat Duchenne muscular dystrophy (DMD). Solid plans to resume enrollment under...
11:27 AM, Jun 22, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Novo's oral GLP-1 analog meets primary in Phase IIIa trials compared with approved therapies

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) reported that oral diabetes candidate semaglutide was at least non-inferior to two approved therapies in reducing HbA1c and led to greater body weight reductions than both drugs in a...
11:27 AM, Jun 22, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Heron's pain candidate meets in Phase IIb ahead of NDA

Heron Therapeutics Inc. (NASDAQ:HRTX) reported that HTX-011 met the primary endpoint in a pair of Phase IIb trials to treat postoperative pain. Heron intends to submit an NDA to FDA next half for the candidate....
11:27 AM, Jun 22, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Sarepta's DMD candidate leads to microdystrophin expression of 76.2% in Phase I/IIa

Sarepta Therapeutics Inc. (NASDAQ:SRPT) reported on June 19 preliminary data from a Phase I/IIa trial evaluating AAVrh74.MHCK7.micro-Dystrophin to treat Duchenne muscular dystrophy (DMD). In three DMD patients in the open-label, U.S. trial, the microdystrophin gene therapy...
11:26 AM, Jun 22, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Teva discontinues Phase III chronic cluster headache trial of fremanezumab

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) discontinued a Phase III trial of fremanezumab (TEV-48125) to prevent chronic cluster headache based on a prespecified futility analysis. The company said a Phase III trial of the...
11:26 AM, Jun 22, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

bluebird on track to submit MAA to EMA for LentiGlobin

bluebird bio Inc. (NASDAQ:BLUE) said it is on track to submit an MAA to EMA next half for its LentiGlobin BB305 to treat beta-thalassemia and reported additional data from three studies of the gene therapy....

Pages